Medicare will begin covering weight loss drugs in 2026 for the first time under a pricing agreement announced by the White House, according to a Nov. 6 press release. The agreements with Eli Lilly and ...

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower ...

Open Educational Resources (OERs) are freely accessible and openly licensed teaching materials, such as textbooks, videos, and assignments. These resources empower instructors to deliver more ...

Cleveland Clinic researchers found that individuals with a variant of the Neurobeachin gene were more likely to lose weight when using drugs like Ozempic, Wegovy and Zepbound. People with a specific ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...

A new drug has shown promise as a type 2 diabetes and weight loss treatment—potentially offering an new rival to drugs like Ozempic. Ecnoglutide—a new once-weekly GLP-1 receptor agonist injection ...

Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which ...

Mounjaro reduces major heart problems by 8% versus Trulicity in trial Death from any cause was 16% lower for patients on Mounjaro versus Trulicity Safety profile similar for both drugs July 31 ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity. Stream ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. But what about Eli ...